emerging approaches in targeting cldn18.2 in gastric cancer
Published 3 months ago • 111 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
8:12
gastroesophageal cancer: emerging approaches
-
1:00
evaluating the emerging role of cellular therapies in gi cancers
-
6:14
novel targeted approaches in gastroesophageal cancer
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
6:00
claudin18.2: an emerging biomarker and its significance as a therapeutic target in g/gej cancers
-
1:08
the role of neoadjuvant immunotherapy in msi-high gastric cancer
-
6:00
what is the evidence supporting cldn18.2 targeting in frontline management of g/gej cancers
-
0:34
expanding indications for a cldn18.2-specific car t-cell therapy in gi cancers
-
0:35
gastrointestinal cancer trials to watch out for in 2023
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
1:33
transtar101: osemitamab, a novel cldn18.2 inhibitor, in solid tumors
-
1:14
gastric cancer updates at esmo 2022
-
8:41
fast: a phase iii trial of an anti-cldn18.2 antibody gej adenocarcinoma
-
3:03
targeted therapies for gastroesophageal adenocarcinoma